查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2081836

生物製藥市場：2026-2032年全球市場預測（按產品類型、技術、給藥途徑、劑型、儲存條件、治療領域、最終用戶、分銷管道和病患細分）

Biologics Market by Product Type, Technology, Route Of Administration, Presentation Format, Storage Condition, Therapeutic Area, End User, Distribution Channel, Patient Population - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，生物製藥市場將成長至 7,191.7 億美元，複合年成長率為 6.61%。

主要市場統計數據
基準年 2025 4594.5億美元
預計年份：2026年 4863.7億美元
預測年份 2032 7191.7億美元
複合年成長率 (%) 6.61%

生物製藥執行摘要：精準醫療開啟醫療保健新紀元

生物製藥正在透過將免疫學、細胞生物學、重組DNA技術和精準醫學領域的最新進展轉化為針對疾病機制的高特異性療法，從而變革醫療保健。生物製藥領域涵蓋單株抗體、重組蛋白、疫苗、血液和血漿製品、細胞和基因療法、抗體藥物複合體（ADC）以及生物類似藥，這些療法正被應用於腫瘤學、自體免疫疾病、罕見疾病、感染疾病、代謝性疾病和神經病學等領域。

生物製藥領域的變革性變化

生物製藥領域正在經歷一場結構性轉變，從以產量為導向的製藥模式轉向以科學主導、注重治療效果的創新模式。儘管單株抗體仍是核心收入來源，但雙特異性抗體、抗體藥物複合體（ADC）、mRNA平台、細胞療法和基因療法正在拓展生物製藥的定義。這項轉變推動了對細胞株開發、病毒載體生產、一次性生物製程、低溫運輸物流、療效測試和等效性分析等專業能力的需求成長。

人工智慧對生物製藥的累積影響

人工智慧（AI）正成為生物製藥發現、開發、生產和商業化各個階段的實質驅動力。在藥物發現階段，AI驅動的蛋白質建模、抗體設計、抗原決定位預測和可行性篩檢有助於減輕實驗負擔並改善候選化合物的選擇。在臨床開發階段，機器學習正在支援生物標記發現、臨床實驗分層、研究中心選擇、方案最佳化、藥物安全性監測訊號檢測和真實世界數據（RWE）分析。

全球生物製藥市場的關鍵區域洞察

北美地區在生物製藥領域持續保持領先地位，這得益於資金籌措、先進的臨床試驗基礎設施、強力的智慧財產權保護以及成熟的生物製藥和生物類似藥監管體系。美國在該地區扮演著核心角色，這得益於美國食品藥物管理局（FDA）的審查能力、大型製造群、先進的專科藥物獲取途徑以及強大的生物醫學投資。加拿大則透過其臨床研究網路、對生物製藥製造的投資以及日益重視生物相似藥評估以控制成本的公共醫保體係做出貢獻。

團隊對生物製藥策略的關鍵見解

七國集團（美國、日本、德國、法國、英國、義大利和加拿大）憑藉其先進的研究生態系統、完善的醫療保險報銷機制和成熟的監管體系，在生物製藥創新領域仍發揮核心作用。這些市場塑造臨床標準、定價爭議、藥物安全監測預期、生物相似藥政策以及全球生物製藥療法市場格局。

來自關鍵國家的洞見將推動生物製藥產業的成長

美國是全球最具影響力的生物製藥市場，這主要得益於FDA的批准、特藥的高使用率、先進的臨床研究以及生物技術領域強勁的資本累積。儘管生物相似藥在腫瘤學和免疫學等治療領域正日益普及，但其應用程度取決於醫保報銷機制、處方藥目錄管理以及對醫療服務提供者的獎勵。加拿大正著力於省級層級制定生物相似藥的准入、成本控制和過渡政策，而墨西哥則透過私人醫療保健、公共採購和監管現代化來擴大對生物製藥的需求。

為生物製藥行業領導者提供的實用建議

產業供應商應優先發展差異化的生物製劑產品線，並以可靠的生物標記策略、具有臨床意義的終點指標和早期以支付方為導向的證據為支持。開發單株抗體、雙特異性抗體、抗體藥物複合體(ADC)、細胞療法、基因療法、疫苗和生物類似藥的機構應從早期階段就制定整合計劃，將標靶驗證、開發可行性、生產規模化、監管策略和市場進入聯繫起來。

生物製藥市場情報調查方法

本執行摘要採用系統化的二手研究途徑編寫，重點關注檢驗的公開資訊資訊來源和行業標準證據。主要資訊來源包括：美國食品藥物管理局 (FDA)、歐洲藥品管理局 (EMA)、加拿大衛生署、日本藥品和醫療器材管理局 (PMDA)、中國國家藥品監督管理局 (NMPA) 和其他國家監管機構的監管文件；世界衛生組織 (WHO)、經濟合作與發展組織 (OECD) 和各國衛生署的政策資訊；世界衛生組織 (WHO)、經濟合作與發展組織 (OECD) 和各國衛生部門的政策資訊；

結論：生技藥品領域的領導地位需要科學、規模和可近性。

生技藥品兼具科學的精確性與重要的臨床與策略機遇，是醫藥創新的核心。先進療法、生物相似藥的競爭、人工智慧驅動的研發、不斷擴大的區域製造地以及監管機構和保險公司日益嚴格的證據要求，正在重塑這一格局。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 生物製藥市場：依產品類型分類

  • 血液因子製劑
  • 細胞療法
    • CAR-T療法
    • 幹細胞療法
  • 基因治療
  • 單株抗體
  • 重組蛋白
  • 疫苗

第8章：生物製藥市場：依技術分類

  • 細胞培養技術
  • 基因編輯技術
    • CRISPR
    • TALENs
    • 鋅指核酸酶
  • 融合瘤技術
  • 重組DNA技術

第9章：生物製藥市場：依給藥途徑分類

  • 肌肉內部
  • 靜脈
  • 皮下

第10章：生物製藥市場：以劑型分類

  • 管瓶
  • 預填充式注射器
  • 墨水匣
  • 自動噴油器

第11章：生物製藥市場：依儲存條件分類

  • 冷藏
  • 冰凍
  • 室溫穩定

第12章：生物製藥市場：依治療領域分類

  • 自體免疫
  • 心血管疾病
  • 感染疾病
  • 代謝性疾病
  • 神經病變
  • 腫瘤學

第13章：生物製藥市場：依最終用戶分類

  • 診所
  • 家庭醫療保健
  • 醫院
  • 研究機構

第14章 生物製藥市場：依通路分類

  • 醫院藥房
  • 線上管道
  • 零售藥房

第15章 生物製藥市場：依病患群體分類

  • 兒童
  • 成人
  • 老年人

第16章 生物製藥市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第17章 生物製藥市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第18章 生物製藥市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第20章：公司簡介

  • AbbVie Inc.
  • Ajinomoto Bio-Pharma Services
  • Amgen Inc.
  • Amneal Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Aurobindo Pharma Limited
  • Avantor, Inc.
  • Baxter International Inc.
  • Bayer AG
  • Becton, Dickinson and Company
  • Biogen Inc.
  • BioNTech SE
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Catalent Inc.
  • Celltrion Inc.
  • Chugai Pharmaceutical Co., Ltd.
  • Cipla Limited
  • CSL Limited
  • Danaher Corporation
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Gilead Sciences Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson Services Inc.
  • Lonza Group AG
  • Merck & Co. Inc.
  • Moderna Inc.
  • Novartis AG
  • Pfizer Inc.
  • Samsung Biologics Co. Ltd.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-4302AC72200D

The Biologics Market is projected to grow by USD 719.17 billion at a CAGR of 6.61% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 459.45 billion
Estimated Year [2026] USD 486.37 billion
Forecast Year [2032] USD 719.17 billion
CAGR (%) 6.61%

Biologics Executive Summary: Precision Therapies Drive the Next Era of Healthcare

Biologics are reshaping healthcare by translating advances in immunology, cell biology, recombinant DNA technology, and precision medicine into therapies that target disease mechanisms with high specificity. The biologics landscape includes monoclonal antibodies, recombinant proteins, vaccines, blood and plasma products, cell and gene therapies, antibody-drug conjugates, and biosimilars used across oncology, autoimmune disease, rare disease, infectious disease, metabolic disorders, and neurology.

Momentum is supported by sustained regulatory approvals, rising chronic disease burden, expanding biologics manufacturing capacity, and the increasing clinical value of targeted therapies. The U.S. FDA's Center for Drug Evaluation and Research approved 55 novel drugs in 2023, including biologic products, while biosimilar adoption continues to broaden following the first U.S. biosimilar approval in 2015 and more than 80 biosimilar approvals in Europe since 2006. For industry leaders, competitive advantage increasingly depends on clinical differentiation, scalable bioprocessing, supply chain resilience, regulatory excellence, and evidence generation across the product lifecycle.

Transformative Shifts in the Biologics Landscape

The biologics landscape is undergoing a structural shift from volume-led pharmaceutical models to science-led, outcome-oriented innovation. Monoclonal antibodies remain a core commercial engine, while bispecific antibodies, antibody-drug conjugates, mRNA platforms, cell therapies, and gene therapies are expanding the definition of biological medicines. This transition is increasing demand for specialized capabilities in cell line development, viral vector production, single-use bioprocessing, cold chain logistics, potency testing, and comparability analytics.

At the same time, biosimilars are changing access and pricing dynamics. Regulatory confidence in biosimilar comparability has strengthened in the United States, Europe, Japan, and several emerging markets, encouraging payer adoption and tender-based competition. The industry is also responding to policy pressure around affordability, including U.S. Medicare drug price negotiation under the Inflation Reduction Act and ongoing European initiatives to improve medicine access. These shifts are pushing manufacturers to balance innovation, cost efficiency, patient access, and lifecycle management with greater discipline.

Cumulative Impact of Artificial Intelligence on Biologics

Artificial intelligence is becoming a practical accelerator across biologics discovery, development, manufacturing, and commercialization. In discovery, AI-enabled protein modeling, antibody design, epitope prediction, and developability screening help reduce experimental burden and improve candidate selection. In clinical development, machine learning supports biomarker discovery, patient stratification, trial site selection, protocol optimization, pharmacovigilance signal detection, and real-world evidence analysis.

The cumulative impact of AI is strongest when data quality, governance, and regulatory traceability are embedded from the start. Biologics development generates complex datasets from omics, imaging, process analytics, bioassays, electronic health records, and manufacturing sensors. Organizations that connect these data streams can improve process control, reduce batch failure risk, support quality-by-design strategies, and accelerate regulatory responses. However, AI deployment must be validated, explainable, and aligned with evolving guidance from agencies such as the FDA, EMA, and ICH to ensure patient safety and compliance.

Key Regional Insights Across Global Biologics Markets

North America remains a leading biologics region due to deep biotech funding, advanced clinical trial infrastructure, strong intellectual property protection, and mature regulatory pathways for biologics and biosimilars. The United States anchors the region, supported by FDA review capacity, major biomanufacturing clusters, high specialty medicine utilization, and strong biomedical investment. Canada contributes through clinical research networks, biologics manufacturing investments, and public reimbursement frameworks that increasingly evaluate biosimilars for cost containment.

Europe combines scientific depth with a well-established biosimilar framework. The European Medicines Agency approved the first biosimilar in 2006, and European markets have accumulated extensive real-world experience with switching and tendering. Germany, France, Italy, Spain, and the United Kingdom remain important centers for biologics consumption, clinical research, and advanced therapy development, while European pharmaceutical policy is emphasizing access, supply security, and innovation competitiveness.

Asia-Pacific is advancing rapidly as China, Japan, South Korea, India, Australia, and ASEAN markets expand biologics development and manufacturing. China has accelerated biologics approvals and domestic innovation, India is a major biosimilar and vaccine manufacturing base, Japan maintains rigorous quality and reimbursement systems, and South Korea has built globally competitive biosimilar capabilities. Latin America is led by Brazil and Mexico, where biologics access is expanding through public health systems, private care growth, and local regulatory modernization. The Middle East, particularly GCC countries, is investing in specialty care infrastructure and national health transformation, while Africa is at an earlier stage but gaining attention for vaccine access, cold chain strengthening, regulatory capacity building, and local production initiatives supported by public health priorities.

Key Group Insights for Biologics Strategy

The G7 remains central to biologics innovation because the United States, Japan, Germany, France, the United Kingdom, Italy, and Canada combine advanced research ecosystems, reimbursement capacity, and mature regulatory systems. These markets shape clinical standards, pricing debates, pharmacovigilance expectations, biosimilar policies, and global launch sequencing for biologic therapies.

The European Union is a global reference point for biosimilar regulation, centralized marketing authorization, and health technology assessment coordination. Its policy direction increasingly connects medicine availability, manufacturing resilience, and competitiveness in life sciences. BRICS countries are becoming more influential as China, India, Brazil, Russia, and South Africa expand domestic manufacturing, biosimilar development, vaccine production, and public-sector procurement. China and India are especially important to cost-competitive biologics supply and clinical development scale, while Brazil and South Africa strengthen regional access priorities through public health systems.

ASEAN is emerging as a growth corridor as Indonesia, Thailand, Vietnam, Malaysia, Singapore, and the Philippines expand specialty care access and regulatory harmonization efforts. Singapore is a high-value biomanufacturing and regional headquarters hub, while larger ASEAN markets drive patient access needs across oncology, autoimmune disease, and diabetes care. GCC countries are investing in oncology, diabetes, immunology, and rare disease care through hospital modernization and national health transformation programs. NATO markets overlap significantly with North America and Europe, making them strategically important for supply security, regulatory alignment, emergency preparedness, and resilient pharmaceutical logistics.

Key Country Insights Shaping Biologics Growth

The United States is the most influential biologics market, driven by FDA approvals, high specialty drug use, advanced clinical research, and strong biotech capital formation. Biosimilar uptake has improved in therapeutic areas such as oncology and immunology, although adoption varies by reimbursement design, formulary management, and provider incentives. Canada is focused on access, cost containment, and biosimilar switching policies across provinces, while Mexico is expanding biologics demand through private healthcare, public procurement, and regulatory modernization.

Brazil leads Latin America in biologics consumption and local production ambitions, supported by a large public health system and technology transfer models. The United Kingdom remains a strong life sciences hub with NHS-led biosimilar adoption and advanced therapy initiatives. Germany combines high healthcare spending with strong biopharmaceutical manufacturing and early access pathways, while France emphasizes innovation, reimbursement evaluation, and domestic health sovereignty. Italy and Spain continue to expand biosimilar use through regional procurement and hospital-based prescribing. Russia maintains domestic production priorities and import substitution policies, although geopolitical and supply chain constraints affect international participation.

China has become a major biologics innovation and manufacturing market, supported by regulatory reforms, domestic antibody pipelines, and expanding oncology care. India is a global supplier of vaccines and biosimilars, with competitive manufacturing economics and rising domestic demand. Japan offers a high-quality regulatory environment and strong demand for oncology, immunology, and regenerative medicine. Australia contributes through clinical trials, reimbursement access, and biomedical research, while South Korea is recognized for large-scale biosimilar manufacturing, contract development capabilities, and global biologics exports.

Actionable Recommendations for Biologics Industry Leaders

Industry vendors should prioritize differentiated biologics pipelines supported by strong biomarker strategies, clinically meaningful endpoints, and early payer evidence. Organizations developing monoclonal antibodies, bispecifics, antibody-drug conjugates, cell therapies, gene therapies, vaccines, and biosimilars should build integrated plans that connect target validation, developability, manufacturing scalability, regulatory strategy, and market access from the earliest stages.

Manufacturers should invest in flexible bioprocessing, dual sourcing, raw material risk management, cold chain visibility, and digital quality systems to reduce supply disruptions. AI and automation should be deployed where they can be validated and measured, including process analytics, deviation detection, literature surveillance, clinical trial optimization, and pharmacovigilance workflows. Commercial teams should strengthen real-world evidence generation, physician education, patient support, and biosimilar confidence programs to improve adoption, adherence, and persistence.

Strategic partnerships with contract development and manufacturing organizations, academic centers, diagnostics specialists, healthcare systems, and regional distributors can accelerate geographic expansion. Companies should also monitor regulatory convergence, interchangeability policies, pharmacovigilance requirements, health technology assessment reforms, and drug pricing policies to align launch strategy with local evidence expectations and affordability priorities.

Research Methodology for Biologics Market Intelligence

This executive summary is developed using a structured secondary research approach focused on verified public sources and industry-standard evidence. Key inputs include regulatory agency publications from the FDA, EMA, Health Canada, Japan's PMDA, China's NMPA, and other national authorities; policy information from the World Health Organization, OECD, and national health ministries; clinical trial registries; peer-reviewed literature; pharmacovigilance resources; reimbursement documentation; and public biomanufacturing policy updates.

The methodology evaluates biologics through product class, therapeutic area, regulatory pathway, manufacturing model, regional demand indicators, reimbursement environment, and competitive intensity. Insights are triangulated across approval trends, biosimilar adoption evidence, biomanufacturing investments, clinical pipeline signals, public health priorities, and healthcare policy developments. Emphasis is placed on data-backed interpretation rather than unsupported forecasts, ensuring that the analysis remains credible for executives, investors, manufacturers, and market access leaders.

Conclusion: Biologics Leadership Requires Science, Scale, and Access

Biologics are at the center of pharmaceutical innovation, combining scientific precision with substantial clinical and strategic opportunity. The landscape is being reshaped by advanced modalities, biosimilar competition, AI-enabled development, regional manufacturing expansion, and stronger evidence requirements from regulators and payers.

Organizations that combine differentiated science with scalable manufacturing, trusted quality systems, resilient supply chains, and market-specific access strategies will be best positioned to lead. As healthcare systems pursue better outcomes and sustainable spending, biologics developers and manufacturers must prove value through clinical performance, affordability, regulatory confidence, and reliable global supply.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Biologics Market, by Product Type

  • 7.1. Blood Factor Products
  • 7.2. Cell Therapies
    • 7.2.1. CAR-T Therapies
    • 7.2.2. Stem Cell Therapy
  • 7.3. Gene Therapies
  • 7.4. Monoclonal Antibodies
  • 7.5. Recombinant Proteins
  • 7.6. Vaccines

8. Biologics Market, by Technology

  • 8.1. Cell Culture Technology
  • 8.2. Gene Editing Technology
    • 8.2.1. CRISPR
    • 8.2.2. TALENs
    • 8.2.3. Zinc Finger Nucleases
  • 8.3. Hybridoma Technology
  • 8.4. Recombinant DNA Technology

9. Biologics Market, by Route Of Administration

  • 9.1. Intramuscular
  • 9.2. Intravenous
  • 9.3. Subcutaneous

10. Biologics Market, by Presentation Format

  • 10.1. Vials
  • 10.2. Prefilled Syringes
  • 10.3. Cartridges
  • 10.4. Autoinjectors

11. Biologics Market, by Storage Condition

  • 11.1. Refrigerated
  • 11.2. Frozen
  • 11.3. Room Temperature Stable

12. Biologics Market, by Therapeutic Area

  • 12.1. Autoimmune
  • 12.2. Cardiovascular Diseases
  • 12.3. Infectious Diseases
  • 12.4. Metabolic Disorders
  • 12.5. Neurological Disorders
  • 12.6. Oncology

13. Biologics Market, by End User

  • 13.1. Clinics
  • 13.2. Home Healthcare
  • 13.3. Hospitals
  • 13.4. Research Institutes

14. Biologics Market, by Distribution Channel

  • 14.1. Hospital Pharmacy
  • 14.2. Online Channel
  • 14.3. Retail Pharmacy

15. Biologics Market, by Patient Population

  • 15.1. Pediatric
  • 15.2. Adult
  • 15.3. Geriatric

16. Biologics Market, by Region

  • 16.1. Asia-Pacific
  • 16.2. North America
  • 16.3. Latin America
  • 16.4. Europe
  • 16.5. Middle East
  • 16.6. Africa

17. Biologics Market, by Group

  • 17.1. ASEAN
  • 17.2. GCC
  • 17.3. European Union
  • 17.4. BRICS
  • 17.5. G7
  • 17.6. NATO

18. Biologics Market, by Country

  • 18.1. United States
  • 18.2. Canada
  • 18.3. Mexico
  • 18.4. Brazil
  • 18.5. United Kingdom
  • 18.6. Germany
  • 18.7. France
  • 18.8. Russia
  • 18.9. Italy
  • 18.10. Spain
  • 18.11. China
  • 18.12. India
  • 18.13. Japan
  • 18.14. Australia
  • 18.15. South Korea

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025

20. Company Profiles

  • 20.1. AbbVie Inc.
  • 20.2. Ajinomoto Bio-Pharma Services
  • 20.3. Amgen Inc.
  • 20.4. Amneal Pharmaceuticals, Inc.
  • 20.5. AstraZeneca PLC
  • 20.6. Aurobindo Pharma Limited
  • 20.7. Avantor, Inc.
  • 20.8. Baxter International Inc.
  • 20.9. Bayer AG
  • 20.10. Becton, Dickinson and Company
  • 20.11. Biogen Inc.
  • 20.12. BioNTech SE
  • 20.13. Boehringer Ingelheim International GmbH
  • 20.14. Bristol-Myers Squibb Company
  • 20.15. Catalent Inc.
  • 20.16. Celltrion Inc.
  • 20.17. Chugai Pharmaceutical Co., Ltd.
  • 20.18. Cipla Limited
  • 20.19. CSL Limited
  • 20.20. Danaher Corporation
  • 20.21. Eli Lilly and Company
  • 20.22. F. Hoffmann-La Roche AG
  • 20.23. Gilead Sciences Inc.
  • 20.24. GlaxoSmithKline plc
  • 20.25. Johnson & Johnson Services Inc.
  • 20.26. Lonza Group AG
  • 20.27. Merck & Co. Inc.
  • 20.28. Moderna Inc.
  • 20.29. Novartis AG
  • 20.30. Pfizer Inc.
  • 20.31. Samsung Biologics Co. Ltd.
  • 20.32. Sanofi SA
  • 20.33. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL BIOLOGICS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL BIOLOGICS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL BIOLOGICS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL BIOLOGICS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL BIOLOGICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL BIOLOGICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL BIOLOGICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL BIOLOGICS MARKET SIZE, BY PRESENTATION FORMAT, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL BIOLOGICS MARKET SIZE, BY PRESENTATION FORMAT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL BIOLOGICS MARKET SIZE, BY STORAGE CONDITION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL BIOLOGICS MARKET SIZE, BY STORAGE CONDITION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL BIOLOGICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL BIOLOGICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL BIOLOGICS MARKET SIZE, BY PATIENT POPULATION, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL BIOLOGICS MARKET SIZE, BY PATIENT POPULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL BIOLOGICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 27. GLOBAL BIOLOGICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL BIOLOGICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 29. GLOBAL BIOLOGICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL BIOLOGICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 31. GLOBAL BIOLOGICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BIOLOGICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BLOOD FACTOR PRODUCTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BLOOD FACTOR PRODUCTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BLOOD FACTOR PRODUCTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CELL THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CELL THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CELL THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CAR-T THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CAR-T THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CAR-T THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL STEM CELL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL STEM CELL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GENE THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GENE THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GENE THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CELL CULTURE TECHNOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CELL CULTURE TECHNOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CELL CULTURE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GENE EDITING TECHNOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GENE EDITING TECHNOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GENE EDITING TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CRISPR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CRISPR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CRISPR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL TALENS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL TALENS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL TALENS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ZINC FINGER NUCLEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ZINC FINGER NUCLEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ZINC FINGER NUCLEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL HYBRIDOMA TECHNOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL HYBRIDOMA TECHNOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL HYBRIDOMA TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL RECOMBINANT DNA TECHNOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL RECOMBINANT DNA TECHNOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL RECOMBINANT DNA TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BIOLOGICS MARKET SIZE, BY PRESENTATION FORMAT, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL VIALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL VIALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL VIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PREFILLED SYRINGES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PREFILLED SYRINGES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PREFILLED SYRINGES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CARTRIDGES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CARTRIDGES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CARTRIDGES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL AUTOINJECTORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL AUTOINJECTORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL AUTOINJECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BIOLOGICS MARKET SIZE, BY STORAGE CONDITION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL REFRIGERATED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL REFRIGERATED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL REFRIGERATED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL FROZEN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL FROZEN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL FROZEN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ROOM TEMPERATURE STABLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ROOM TEMPERATURE STABLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ROOM TEMPERATURE STABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL AUTOIMMUNE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL AUTOIMMUNE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL AUTOIMMUNE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CARDIOVASCULAR DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CARDIOVASCULAR DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CARDIOVASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL METABOLIC DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL METABOLIC DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL METABOLIC DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL HOME HEALTHCARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL HOME HEALTHCARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL HOME HEALTHCARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL ONLINE CHANNEL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL ONLINE CHANNEL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL ONLINE CHANNEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL BIOLOGICS MARKET SIZE, BY PATIENT POPULATION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL ADULT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL ADULT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL BIOLOGICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC BIOLOGICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY PRESENTATION FORMAT, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY STORAGE CONDITION, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY PATIENT POPULATION, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA BIOLOGICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA BIOLOGICS MARKET SIZE, BY PRESENTATION FORMAT, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA BIOLOGICS MARKET SIZE, BY STORAGE CONDITION, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA BIOLOGICS MARKET SIZE, BY PATIENT POPULATION, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA BIOLOGICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA BIOLOGICS MARKET SIZE, BY PRESENTATION FORMAT, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA BIOLOGICS MARKET SIZE, BY STORAGE CONDITION, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA BIOLOGICS MARKET SIZE, BY PATIENT POPULATION, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE BIOLOGICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE BIOLOGICS MARKET SIZE, BY PRESENTATION FORMAT, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE BIOLOGICS MARKET SIZE, BY STORAGE CONDITION, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE BIOLOGICS MARKET SIZE, BY PATIENT POPULATION, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST BIOLOGICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST BIOLOGICS MARKET SIZE, BY PRESENTATION FORMAT, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST BIOLOGICS MARKET SIZE, BY STORAGE CONDITION, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST BIOLOGICS MARKET SIZE, BY PATIENT POPULATION, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA BIOLOGICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA BIOLOGICS MARKET SIZE, BY PRESENTATION FORMAT, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA BIOLOGICS MARKET SIZE, BY STORAGE CONDITION, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 206. AFRICA BIOLOGICS MARKET SIZE, BY PATIENT POPULATION, 2018-2032 (USD MILLION)
  • TABLE 207. GLOBAL BIOLOGICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN BIOLOGICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 214. ASEAN BIOLOGICS MARKET SIZE, BY PRESENTATION FORMAT, 2018-2032 (USD MILLION)
  • TABLE 215. ASEAN BIOLOGICS MARKET SIZE, BY STORAGE CONDITION, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 218. ASEAN BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 219. ASEAN BIOLOGICS MARKET SIZE, BY PATIENT POPULATION, 2018-2032 (USD MILLION)
  • TABLE 220. GCC BIOLOGICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 221. GCC BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. GCC BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 223. GCC BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 224. GCC BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 225. GCC BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 226. GCC BIOLOGICS MARKET SIZE, BY PRESENTATION FORMAT, 2018-2032 (USD MILLION)
  • TABLE 227. GCC BIOLOGICS MARKET SIZE, BY STORAGE CONDITION, 2018-2032 (USD MILLION)
  • TABLE 228. GCC BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 229. GCC BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 230. GCC BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 231. GCC BIOLOGICS MARKET SIZE, BY PATIENT POPULATION, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPEAN UNION BIOLOGICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPEAN UNION BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPEAN UNION BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPEAN UNION BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPEAN UNION BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPEAN UNION BIOLOGICS MARKET SIZE, BY PRESENTATION FORMAT, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION BIOLOGICS MARKET SIZE, BY STORAGE CONDITION, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPEAN UNION BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPEAN UNION BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPEAN UNION BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION BIOLOGICS MARKET SIZE, BY PATIENT POPULATION, 2018-2032 (USD MILLION)
  • TABLE 244. BRICS BIOLOGICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 245. BRICS BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. BRICS BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 247. BRICS BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 248. BRICS BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 249. BRICS BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 250. BRICS BIOLOGICS MARKET SIZE, BY PRESENTATION FORMAT, 2018-2032 (USD MILLION)
  • TABLE 251. BRICS BIOLOGICS MARKET SIZE, BY STORAGE CONDITION, 2018-2032 (USD MILLION)
  • TABLE 252. BRICS BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 253. BRICS BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 254. BRICS BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 255. BRICS BIOLOGICS MARKET SIZE, BY PATIENT POPULATION, 2018-2032 (USD MILLION)
  • TABLE 256. G7 BIOLOGICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 257. G7 BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. G7 BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 259. G7 BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 260. G7 BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 261. G7 BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 262. G7 BIOLOGICS MARKET SIZE, BY PRESENTATION FORMAT, 2018-2032 (USD MILLION)
  • TABLE 263. G7 BIOLOGICS MARKET SIZE, BY STORAGE CONDITION, 2018-2032 (USD MILLION)
  • TABLE 264. G7 BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 265. G7 BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 266. G7 BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 267. G7 BIOLOGICS MARKET SIZE, BY PATIENT POPULATION, 2018-2032 (USD MILLION)
  • TABLE 268. NATO BIOLOGICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 269. NATO BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 270. NATO BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 271. NATO BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 272. NATO BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 273. NATO BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 274. NATO BIOLOGICS MARKET SIZE, BY PRESENTATION FORMAT, 2018-2032 (USD MILLION)
  • TABLE 275. NATO BIOLOGICS MARKET SIZE, BY STORAGE CONDITION, 2018-2032 (USD MILLION)
  • TABLE 276. NATO BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 277. NATO BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 278. NATO BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 279. NATO BIOLOGICS MARKET SIZE, BY PATIENT POPULATION, 2018-2032 (USD MILLION)
  • TABLE 280. GLOBAL BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 281. UNITED STATES BIOLOGICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 282. UNITED STATES BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 283. UNITED STATES BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 284. UNITED STATES BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 285. UNITED STATES BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 286. UNITED STATES BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 287. UNITED STATES BIOLOGICS MARKET SIZE, BY PRESENTATION FORMAT, 2018-2032 (USD MILLION)
  • TABLE 288. UNITED STATES BIOLOGICS MARKET SIZE, BY STORAGE CONDITION, 2018-2032 (USD MILLION)
  • TABLE 289. UNITED STATES BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 290. UNITED STATES BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 291. UNITED STATES BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 292. UNITED STATES BIOLOGICS MARKET SIZE, BY PATIENT POPULATION, 2018-2032 (USD MILLION)
  • TABLE 293. CANADA BIOLOGICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 294. CANADA BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 295. CANADA BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 296. CANADA BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 297. CANADA BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 298. CANADA BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 299. CANADA BIOLOGICS MARKET SIZE, BY PRESENTATION FORMAT, 2018-2032 (USD MILLION)
  • TABLE 300. CANADA BIOLOGICS MARKET SIZE, BY STORAGE CONDITION, 2018-2032 (USD MILLION)
  • TABLE 301. CANADA BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 302. CANADA BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 303. CANADA BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 304. CANADA BIOLOGICS MARKET SIZE, BY PATIENT POPULATION, 2018-2032 (USD MILLION)
  • TABLE 305. MEXICO BIOLOGICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 306. MEXICO BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 307. MEXICO BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 308. MEXICO BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 309. MEXICO BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 310. MEXICO BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 311. MEXICO BIOLOGICS MARKET SIZE, BY PRESENTATION FORMAT, 2018-2032 (USD MILLION)
  • TABLE 312. MEXICO BIOLOGICS MARKET SIZE, BY STORAGE CONDITION, 2018-2032 (USD MILLION)
  • TABLE 313. MEXICO BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 314. MEXICO BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 315. MEXICO BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 316. MEXICO BIOLOGICS MARKET SIZE, BY PATIENT POPULATION, 2018-2032 (USD MILLION)
  • TABLE 317. BRAZIL BIOLOGICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 318. BRAZIL BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 319. BRAZIL BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 320. BRAZIL BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 321. BRAZIL BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 322. BRAZIL BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 323. BRAZIL BIOLOGICS MARKET SIZE, BY PRESENTATION FORMAT, 2018-2032 (USD MILLION)
  • TABLE 324. BRAZIL BIOLOGICS MARKET SIZE, BY STORAGE CONDITION, 2018-2032 (USD MILLION)
  • TABLE 325. BRAZIL BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 326. BRAZIL BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 327. BRAZIL BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 328. BRAZIL BIOLOGICS MARKET SIZE, BY PATIENT POPULATION, 2018-2032 (USD MILLION)
  • TABLE 329. UNITED KINGDOM BIOLOGICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 330. UNITED KINGDOM BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 331. UNITED KINGDOM BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 332. UNITED KINGDOM BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 333. UNITED KINGDOM BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 334. UNITED KINGDOM BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 335. UNITED KINGDOM BIOLOGICS MARKET SIZE, BY PRESENTATION FORMAT, 2018-2032 (USD MILLION)
  • TABLE 336. UNITED KINGDOM BIOLOGICS MARKET SIZE, BY STORAGE CONDITION, 2018-2032 (USD MILLION)
  • TABLE 337. UNITED KINGDOM BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 338. UNITED KINGDOM BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 339. UNITED KINGDOM BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 340. UNITED KINGDOM BIOLOGICS MARKET SIZE, BY PATIENT POPULATION, 2018-2032 (USD MILLION)
  • TABLE 341. GERMANY BIOLOGICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 342. GERMANY BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 343. GERMANY BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 344. GERMANY BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 345. GERMANY BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 346. GERMANY BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 347. GERMANY BIOLOGICS MARKET SIZE, BY PRESENTATION FORMAT, 2018-2032 (USD MILLION)
  • TABLE 348. GERMANY BIOLOGICS MARKET SIZE, BY STORAGE CONDITION, 2018-2032 (USD MILLION)
  • TABLE 349. GERMANY BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 350. GERMANY BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 351. GERMANY BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 352. GERMANY BIOLOGICS MARKET SIZE, BY PATIENT POPULATION, 2018-2032 (USD MILLION)
  • TABLE 353. FRANCE BIOLOGICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 354. FRANCE BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 355. FRANCE BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 356. FRANCE BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 357. FRANCE BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 358. FRANCE BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 359. FRANCE BIOLOGICS MARKET SIZE, BY PRESENTATION FORMAT, 2018-2032 (USD MILLION)
  • TABLE 360. FRANCE BIOLOGICS MARKET SIZE, BY STORAGE CONDITION, 2018-2032 (USD MILLION)
  • TABLE 361. FRANCE BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 362. FRANCE BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 363. FRANCE BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 364. FRANCE BIOLOGICS MARKET SIZE, BY PATIENT POPULATION, 2018-2032 (USD MILLION)
  • TABLE 365. RUSSIA BIOLOGICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 366. RUSSIA BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 367. RUSSIA BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 368. RUSSIA BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 369. RUSSIA BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 370. RUSSIA BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 371. RUSSIA BIOLOGICS MARKET SIZE, BY PRESENTATION FORMAT, 2018-2032 (USD MILLION)
  • TABLE 372. RUSSIA BIOLOGICS MARKET SIZE, BY STORAGE CONDITION, 2018-2032 (USD MILLION)
  • TABLE 373. RUSSIA BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 374. RUSSIA BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 375. RUSSIA BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 376. RUSSIA BIOLOGICS MARKET SIZE, BY PATIENT POPULATION, 2018-2032 (USD MILLION)
  • TABLE 377. ITALY BIOLOGICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 378. ITALY BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 379. ITALY BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 380. ITALY BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 381. ITALY BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 382. ITALY BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 383. ITALY BIOLOGICS MARKET SIZE, BY PRESENTATION FORMAT, 2018-2032 (USD MILLION)
  • TABLE 384. ITALY BIOLOGICS MARKET SIZE, BY STORAGE CONDITION, 2018-2032 (USD MILLION)
  • TABLE 385. ITALY BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 386. ITALY BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 387. ITALY BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 388. ITALY BIOLOGICS MARKET SIZE, BY PATIENT POPULATION, 2018-2032 (USD MILLION)
  • TABLE 389. SP